JAZZ PHARMACEUTICALS PLC

NASDAQ: JAZZ (Jazz Pharmaceuticals plc)

Last update: 04 Jul, 2:49PM

109.45

-0.47 (-0.43%)

Previous Close 109.92
Open 109.50
Volume 327,049
Avg. Volume (3M) 1,070,609
Market Cap 6,622,928,896
Price / Earnings (TTM) 14.87
Price / Earnings (Forward) 12.17
Price / Sales 1.73
Price / Book 1.55
52 Weeks Range
95.49 (-12%) — 148.06 (35%)
Earnings Date 30 Jul 2025
Profit Margin 11.86%
Operating Margin (TTM) -2.90%
Diluted EPS (TTM) 7.36
Quarterly Revenue Growth (YOY) -0.50%
Quarterly Earnings Growth (YOY) 103.00%
Total Debt/Equity (MRQ) 129.82%
Current Ratio (MRQ) 3.38
Operating Cash Flow (TTM) 1.56 B
Levered Free Cash Flow (TTM) 1.50 B
Return on Assets (TTM) 3.99%
Return on Equity (TTM) 12.25%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Jazz Pharmaceuticals plc Bearish Bearish

AIStockmoo Score

2.4
Analyst Consensus 4.0
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 2.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
JAZZ 7 B - 14.87 1.55
CGON 2 B - - 2.81
CVAC 1 B - 5.81 1.62
REPL 861 M - - 1.74
VIR 731 M - - 0.720
ZVRA 616 M - - 12.54

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 3.07%
% Held by Institutions 101.94%
52 Weeks Range
95.49 (-12%) — 148.06 (35%)
Price Target Range
147.00 (34%) — 202.00 (84%)
High 202.00 (Needham, 84.56%) Buy
Median 166.00 (51.67%)
Low 147.00 (Piper Sandler, 34.31%) Buy
Average 168.40 (53.86%)
Total 5 Buy
Avg. Price @ Call 103.25
Firm Date Target Price Call Price @ Call
Needham 11 Jun 2025 202.00 (84.56%) Buy 110.50
03 Jun 2025 202.00 (84.56%) Buy 110.32
Baird 07 May 2025 155.00 (41.62%) Buy 101.44
Morgan Stanley 07 May 2025 166.00 (51.67%) Buy 101.44
Piper Sandler 07 May 2025 147.00 (34.31%) Buy 101.44
RBC Capital 07 May 2025 172.00 (57.15%) Buy 101.44

No data within this time range.

Date Type Details
10 Jul 2025 Announcement Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
01 Jul 2025 Announcement Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
10 Jun 2025 Announcement Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
09 Jun 2025 Announcement Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
02 Jun 2025 Announcement Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
02 Jun 2025 Announcement Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
29 May 2025 Announcement Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
21 May 2025 Announcement Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
06 May 2025 Announcement Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
30 Apr 2025 Announcement Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
25 Apr 2025 Announcement Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
23 Apr 2025 Announcement Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
22 Apr 2025 Announcement Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
21 Apr 2025 Announcement Jazz Pharmaceuticals Completes Acquisition of Chimerix
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria